BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
July 30, 2019 07:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
June 20, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
May 06, 2019 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report First Quarter 2019 Financial Results
April 25, 2019 16:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
February 04, 2019 08:03 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
January 15, 2019 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
November 08, 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
BioDelivery Sciences Announces Changes to its Executive Leadership Team
October 29, 2018 08:30 ET
|
BioDelivery Sciences International, Inc.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 ...
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
October 23, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...